GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (FRA:8AP) » Definitions » Cyclically Adjusted Book per Share

Agios Pharmaceuticals (FRA:8AP) Cyclically Adjusted Book per Share : €14.72 (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Agios Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Agios Pharmaceuticals's adjusted book value per share for the three months ended in Sep. 2024 was €25.703. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €14.72 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Agios Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 9.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-12-12), Agios Pharmaceuticals's current stock price is €43.40. Agios Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was €14.72. Agios Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 2.95.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Agios Pharmaceuticals was 3.81. The lowest was 1.35. And the median was 2.02.


Agios Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Agios Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals Cyclically Adjusted Book per Share Chart

Agios Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 10.00 11.84 13.70

Agios Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.86 13.70 14.04 14.63 14.72

Competitive Comparison of Agios Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Agios Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agios Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Agios Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Agios Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book= Book Value per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=25.703/133.0289*133.0289
=25.703

Current CPI (Sep. 2024) = 133.0289.

Agios Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201412 9.276 99.070 12.456
201503 10.576 99.621 14.123
201506 9.628 100.684 12.721
201509 8.901 100.392 11.795
201512 8.404 99.792 11.203
201603 7.875 100.470 10.427
201606 6.765 101.688 8.850
201609 8.514 101.861 11.119
201612 8.052 101.863 10.516
201703 6.781 102.862 8.770
201706 9.370 103.349 12.061
201709 7.762 104.136 9.916
201712 6.499 104.011 8.312
201803 12.200 105.290 15.414
201806 12.163 106.317 15.219
201809 11.200 106.507 13.989
201812 10.381 105.998 13.028
201903 9.358 107.251 11.607
201906 8.024 108.070 9.877
201909 6.913 108.329 8.489
201912 8.428 108.420 10.341
202003 8.226 108.902 10.048
202006 7.181 108.767 8.783
202009 5.895 109.815 7.141
202012 4.739 109.897 5.737
202103 27.634 111.754 32.895
202106 23.854 114.631 27.682
202109 21.668 115.734 24.906
202112 21.044 117.630 23.799
202203 20.015 121.301 21.950
202206 19.399 125.017 20.642
202209 19.322 125.227 20.526
202212 18.880 125.222 20.057
202303 17.431 127.348 18.209
202306 15.968 128.729 16.501
202309 14.870 129.860 15.233
202312 13.293 129.419 13.664
202403 12.060 131.776 12.175
202406 10.789 132.554 10.828
202409 25.703 133.029 25.703

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Agios Pharmaceuticals  (FRA:8AP) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Agios Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=43.40/14.72
=2.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Agios Pharmaceuticals was 3.81. The lowest was 1.35. And the median was 2.02.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Agios Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Agios Pharmaceuticals Business Description

Industry
Traded in Other Exchanges
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Agios Pharmaceuticals Headlines

No Headlines